Navigation Links
The potent anti-leukemia activity of Berbamine

Chronic myeloid leukemia (CML) is a pluripotent hematopoietic stem cell disorder characterized by accumulation of mature and immature granulocytes in peripheral blood and bone marrow due to uncontrolled growth // and resistance to apoptosis. The dysregulated activity of the bcr/abl oncoprotein tyrosine kinase, which is encoded by the bcr?abl fusion gene, has been shown to be responsible for the malignant phenotypes.

Gleevec, which is an inhibitor of the bcr/abl tyrosine kinase, has been a remarkable success for the treatment of CML. However, a significant proportion of patients chronically treated with Gleevec develop resistance. Thus, new approaches that override the resistance are crucial to the development of curative therapies for CML.

A recent study, to be published in Leukemia Research (available online 14 July 2005) describes the anti-leukemia activity of a natural small molecular compound, berbamine from plant Berberis amurensis that can selectively induce cell death of both Gleevec-sensitive and -resistant Ph+ CML cells.

Importantly, the results in this study show that berbamine is also active against Gleevec-resistant leukemia cells. It is of interest to note that berbamine down-regulates p210 bcr/abl oncoprotein of Ph+ leukemia cells, suggesting that this compound have different anti-leukemia mechanism from that of Gleevec.

The results indicate that up to 76% of leukemia cells were apoptotic cells after treatment with berbamine at concentration of 16 ì g/ml for 48 h, suggesting that the growth inhibition of berbamine for leukemia cells is caused by apoptosis of leukemia cells. Results also suggest that berbamine-induced apoptosis is mediated via caspase-3-dependent pathway.

Another important feature of berbamine is the very desirable safety that is not often seen in conventional chemotherapeutic agents. In addition, berbamine is widely used to improve normal hematopoiesis and immune function of c ancer patients in China.

The authors conclude that berbamine might be a novel bcr/abl inhibitor with potent anti-leukemia activity, and that the potency of berbamine against both Gleevec-sensitive and -resistant Ph+ leukemia cells, and its distinct mechanism of anti-leukemia activity warrant further investigation of berbamine for the treatment of CML
'"/>




Related medicine news :

1. Hepatitis E virus made impotent
2. Unwed mothers find it difficult to attract potential life partner
3. Unpasteurised juices found to be potential health hazards
4. The many facets of milk and its health potential
5. Artificial sweetener, Aspartame, may be the potential cause of lymphoma, leukaemia
6. Alcohol a potential carcinogen: knocking on the door: pay heed!
7. A potent causative agent of dental flourosis: Fluoride
8. Quebec arming itself to combat a potential influenza pandemic
9. Smoking Is a Vital Cause among Impotent Men
10. Pluripotent ESC, To Serve As an Effective Therapy for Many Diseases
11. Estrogen also a potential neurotransmitter
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping ... fitness app. The fitness app plans to fix the two major problems leading the fitness ... size fits all type program , They don’t eliminate all the reasons people ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American Institutes ... Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , ... advance care planning, healthcare costs and patient and family engagement. , AIR researchers ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
(Date:6/24/2016)... According to a new market ... Needles, Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, ... of Purchase (Retail, Non-Retail) - Trends & Global Forecasts ... market for the forecast period of 2016 to 2021. ... by 2021 from USD 1.65 Billion in 2016, growing ...
Breaking Medicine Technology: